Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $85.85 | Total: $429.25 |
| 1 | 10 | $72.72 | Total: $727.20 |
| 1 | 25 | $61.61 | Total: $1,540.25 |
| 1 | 50 | $52.52 | Total: $2,626.00 |
| 1 | 100 | $45.45 | Total: $4,545.00 |
Overview
PTC299 ((4-chlorophenyl) (1S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate) is an orally active inhibitor of VEGFA mRNA translation and selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydrolactate dehydrogenase (DHODH).
Chemical Properties
| Molecular Formula | C25H20Cl2N2O3 |
| Molecular Weight | 467.34 |
| CAS Numbers | 1256565-36-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | COc1ccc(cc1)[C@@H]1N(CCc2c1[nH]c1ccc(Cl)cc21)C(=O)Oc1ccc(Cl)cc1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Cao L, et al. Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of DihydroorotateDehydrogenase with Favorable Pharmaceutical Properties. Mol Cancer Ther. 2019 Jan;18[1] 3-16.